BeiGene, Ltd. (NASDAQ:BGNE – Get Rating)’s share price hit a new 52-week high on Friday after SVB Leerink raised their price target on the stock from $236.00 to $300.00. SVB Leerink currently has an outperform rating on the stock. BeiGene traded as high as $285.64 and last traded at $274.57, with a volume of 577 shares traded. The stock had previously closed at $274.50.
BGNE has been the topic of a number of other reports. Daiwa Capital Markets started coverage on shares of BeiGene in a report on Wednesday, January 11th. They issued a “buy” rating and a $308.00 price target on the stock. Cowen upped their price target on shares of BeiGene from $200.00 to $213.00 in a report on Thursday, November 10th. StockNews.com raised shares of BeiGene from a “sell” rating to a “hold” rating in a research report on Saturday, November 19th. Guggenheim upped their price target on shares of BeiGene from $290.00 to $350.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Morgan Stanley upped their price target on shares of BeiGene from $290.00 to $295.00 and gave the stock an “overweight” rating in a research report on Thursday, October 13th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, BeiGene has a consensus rating of “Moderate Buy” and an average target price of $282.14.
Insider Transactions at BeiGene
In other news, CEO John Oyler sold 25,000 shares of the stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $206.84, for a total value of $5,171,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Xiaodong Wang sold 3,013 shares of the stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $211.33, for a total value of $636,737.29. Following the sale, the insider now owns 5,577,556 shares in the company, valued at $1,178,704,909.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Oyler sold 25,000 shares of the stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $206.84, for a total transaction of $5,171,000.00. The disclosure for this sale can be found here. Insiders have sold 43,033 shares of company stock worth $9,407,504 over the last 90 days. 7.50% of the stock is currently owned by company insiders.
Institutional Trading of BeiGene
BeiGene Price Performance
The stock’s fifty day moving average is $217.59 and its 200-day moving average is $185.83. The stock has a market capitalization of $27.70 billion, a PE ratio of -12.48 and a beta of 0.78. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.07 and a quick ratio of 3.87.
BeiGene (NASDAQ:BGNE – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($5.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.02) by ($1.37). The company had revenue of $387.63 million for the quarter, compared to analysts’ expectations of $360.25 million. BeiGene had a negative net margin of 171.94% and a negative return on equity of 38.92%. As a group, equities analysts predict that BeiGene, Ltd. will post -17.64 earnings per share for the current fiscal year.
BeiGene Company Profile
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
- Get a free copy of the StockNews.com research report on BeiGene (BGNE)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.